BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp decreased its position in shares of Becton Dickinson and Co (NYSE:BDX) by 22.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 92,044 shares of the medical instruments supplier’s stock after selling 27,228 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Becton Dickinson and were worth $24,023,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Cornerstone Wealth Management LLC acquired a new position in Becton Dickinson and during the second quarter worth $812,000. CWM LLC lifted its stake in Becton Dickinson and by 390.6% during the second quarter. CWM LLC now owns 785 shares of the medical instruments supplier’s stock worth $188,000 after purchasing an additional 625 shares in the last quarter. Emerald Investment Partners LLC acquired a new position in Becton Dickinson and during the second quarter worth $200,000. HC Financial Advisors Inc. acquired a new position in Becton Dickinson and during the second quarter worth $2,539,000. Finally, Spinnaker Trust lifted its stake in Becton Dickinson and by 91.8% during the second quarter. Spinnaker Trust now owns 10,197 shares of the medical instruments supplier’s stock worth $2,441,000 after purchasing an additional 4,881 shares in the last quarter. 85.19% of the stock is owned by institutional investors and hedge funds.
A number of research analysts have commented on BDX shares. Citigroup decreased their price target on Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating on the stock in a research note on Tuesday, November 13th. Wells Fargo & Co decreased their price target on Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 7th. UBS Group started coverage on Becton Dickinson and in a research note on Tuesday, November 27th. They set a “neutral” rating and a $260.00 price target on the stock. Barclays set a $260.00 price target on Becton Dickinson and and gave the stock a “hold” rating in a research note on Thursday, November 8th. Finally, Morgan Stanley upped their price objective on Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 4th. Six research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $254.20.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.93. Becton Dickinson and had a return on equity of 13.88% and a net margin of 1.47%. The business had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same quarter in the prior year, the company earned $2.40 earnings per share. The company’s revenue was up 39.0% on a year-over-year basis. Analysts predict that Becton Dickinson and Co will post 12.1 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 31st. Stockholders of record on Monday, December 10th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, December 7th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.22%. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.75. Becton Dickinson and’s dividend payout ratio is currently 27.25%.
In related news, Director Timothy M. Ring sold 42,000 shares of the stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total value of $9,956,940.00. Following the transaction, the director now owns 93,688 shares of the company’s stock, valued at $22,210,614.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Vincent A. Forlenza sold 16,866 shares of the stock in a transaction on Tuesday, November 13th. The shares were sold at an average price of $237.61, for a total value of $4,007,530.26. The disclosure for this sale can be found here. Insiders have sold 81,795 shares of company stock worth $19,571,318 in the last ninety days. Corporate insiders own 1.00% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.com-unik.info/2018/12/04/becton-dickinson-and-co-bdx-position-trimmed-by-british-columbia-investment-management-corp.html.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
See Also: Bull Market
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.